MXPA06009335A

MXPA06009335A - Substituted pyrazoline compounds for reducing triglycerides in blood

Info

Publication number: MXPA06009335A
Application number: MXPA/A/2006/009335A
Authority: MX
Inventors: Frigolaconstansa Jordi; Altisen Cuberes Rosa; Silva Gutierrez Bonifacio
Original assignee: Altisen Cuberes Rosa; Frigolaconstansa Jordi; Guitierrez Silva Bonifacio; Laboratorios Dr Esteve Sa
Priority date: 2004-02-17
Filing date: 2006-08-16
Publication date: 2007-04-10

Abstract

The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.

Description

SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS A MEDICINE The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. Triglycerides are the chemical form in which most fats exist in foods as well as in the body. Triglycerides are present in blood plasma and, in association with cholesterol, form plasma lipids. Triglycerides in the blood plasma are derived from fats consumed directly or are synthesized from for example carbohydrates. The superfluous food intake is converted into triglycerides and the fat cells are transported to be stored. The elevated triglycerides can also be a consequence of disease states, such as untreated diabetes mellitus. The excess of triglycerides in the plasma (hypertriglyceridemia) is linked to the occurrence of coronary artery disease and possibly other disorders.

Therefore, the compounds, which have an effect on triglycerides, especially in blood plasma, are useful for the prevention and / or treatment of related disorders. Thus, an object of the present invention is to provide novel compounds for use as active substances in medicaments, which are suitable for regulating especially the reduction of triglyceride levels in blood plasma. Said object is achieved by supplying the substituted pyrazoline compounds of general formula I given below, their stereoisomers, the corresponding salts and the corresponding solvates thereof. It has been found that these compounds have a marked effect on the levels of triglycerides in the blood plasma. Thus, one of the aspects of the present invention relates to substituted pyrazoline compounds of general formula wherein R 1 represents hydrogen or a linear or branched C 1 -4 alkyl group, R 2, R 3 and R 4 independently of one another represents hydrogen, a linear or branched C ?S alkyl group, a linear or branched C?-6 alkoxy group , a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (C = 0) -NHR8 or - (C = 0) -NR8R9 whereby R8 and R9 for each substituent independently represents linear or branched Ca6 alkyl, R5 and R6 independently of each other represents a linear C6-6 alkyl group or branched, a linear or branched C6 alkoxy group, a halogen atom, CH2F, CHF2, CF3 / CN, OH, N02, ~ (C = 0) -R10, SH, SR10, SOR10, NH2, NHR10, NR ^ R11, - (C = 0) -NH2, ~ (C = 0) -NHR10 and - (C ^ -NR ^ R11, whereby R10 and optionally R11 for each substituent independently represents linear or branched C6-6 alkyl, R7 represents hydrogen , a linear or branched C-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R10, SH, SR10, SOR10, NH2, NHR10, NR ^ R11, - (C = 0) -NH2, - (C = 0) -NHR10 and - (C = 0) -? R10R1: L, whereby R10 and optionally R11 for each substituent independently represents linear or branched C6-6 alkyl; with the proviso that if R1 and R7 are H and R5 and R6 both represent Cl in the 3- and 4- position of the phenyl ring none of R2, R3 and R4 may represent F in the 4- position of the phenyl ring if the two others of R2, R3 and R4 both represent H; optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an? -oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof. It is highly preferred if the following condition applies to these compounds according to formula I: with the proviso that if R1 and R7 are H and R5 and R6 both represent Cl in the 3- and 4- position of the phenyl ring none of R2 , R3 and R4 can represent F in the 4- position of the phenyl ring if the other two of R2, R3 and R4 both represent H; These compounds have a surprising effect on the blood levels of the relevant diet substances, for example triglycerides. Preferred saturated or unsaturated linear or branched aliphatic groups, which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl. butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethynyl, propenyl, propynyl, bufenyl and butynyl. In the context of this invention, the alkyl and cycloalkyl radicals are understood as meaning saturated and unsaturated, (but not aromatic), branched, unbranched and cyclic hydrocarbons, which may be unsubstituted or mono or poly-substituted. In these radicals, alkyl Cx_2 represents Cl- or C2- alkyl, C? -3 alkyl represents Cl-, C2- or C3- alkyl, C? _4 alkyl represents Cl-, C2-, C3- or C4- alkyl, C1 alkyl "5 represents Cl-, C2-, C3-, C4-, or C5- alkyl, or C6-6 alkyl represents Cl-, C2-, C3-, C4-, C5- or C6- alkyl, C- alkyl- 7 represents Cl-, C2-, C3-, C4-, C5-, C6- or C7- alkyl, C- -8 alkyl represents Cl-, C2-, C3-, C4-, C5-, C6-, C7 alkyl - or C8-, alkyl Cx-io represents alkyl Cl-, C2-, C3-, C4-, C5-, C6-, 0.1-, C8-, C9- or CIO- and alkyl C? -? 8 represents alkyl Cl -, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, CIO-, CU-, C12-, C13-, C14-, C15-, C16-, C17- or C18- In addition, C3-4 cycloalkyl represents C3- or C4- cycloalkyl, C3-5 cycloalkyl represents C3-, C4- or C5- cycloalkyl, C3-6 cycloalkyl represents C3-, C4-, C5- or C6- cycloalkyl, C3_7 cycloalkyl represents C3-, C4-, C5-, C6- or C7- cycloalkyl, C3_8-cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-, C4_5 cycloalkyl represents cycloalkyl C4- or C5-, C4_6 cycloalkyl represents C4-, C5- or C6- cycloalkyl, C4.7 cycloalkyl represents C4-, C5-, C6- or C7- cycloalkyl, C5_6 cycloalkyl represents C5- or C6-cycloalkyl and C5-cycloalkyl -7 represents C5-, C6- or C7- cycloalkyl. With respect to cycloalkyl, the term also includes saturated cycloalkyls in which one or 2 carbon atoms are replaced by an S, N or O heteroatom. However, mono- or polyunsaturated cycloalkyls preferably monounsaturated without a ring heteroatom in they fall under the term cycloalkyl as long as cycloalkyl is not an aromatic system. The alkyl and cycloalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propynyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, , 1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl, (if it also substitutes CHF2, CF3 or CH2OH) as well as pyrazolinone, oxopyrazoline, [1,4] -dioxane or dioxolane. Here, in relation to alkyl and cycloalkyl - unless otherwise expressly defined - the term substituted in the context of this invention is meant to mean replacement of at least one hydrogen radical by F, Cl, Br, I, NH 2, SH or OH, "polysubstituted" radicals being understood to mean that the replacement has effect on different and on the same atoms several times with the same different substituents, for example three times on the same C atom, as in the case of CF3, or in different places as in the case -CH (OH) -CH = CH-CHC12. the particularly preferred substituents here are F, Cl and OH. With respect to the cycloalkyl, the radical hydrogen fabric can also be replaced by 0C? _6 alkyl or C? -3 alkyl (in each case mono or poly substituted or unsubstituted), in particular methyl, ethyl, n-propyl, i-propyl, CF3, methoxy or ethoxy. The term (CH2) 3_6 is to be understood as meaning -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2- and -CH2-CH2-CH2-CH2- CH2-CH2-, (CH2)? -4 is to be understood as meaning -CH2-, -CH2-CH2-, -CH2-CH2-CH2- and -CH2-CH2-CH2-CH2-, (CH2) 4-s it should be understood as meaning -CH2-CH2-CH2-CH2- and -CH2-CH2-CH2-CH2-CH2-, etc. An aryl radical is understood to mean ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluorantenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be substituted or mono-substituted or poly-substituted. A heteroaryl radical is understood as meaning heterocyclic ring systems having at least one unsaturated ring and may contain one or more heteroatoms from the group consisting of nitrogen, oxygen and / or sulfur and may also be mono or poly-substituted. Examples which may be mentioned of the heteroaryl group are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline.

Here, in relation to aryl and heteroaryl, substituted is meant as meaning substitution of the aryl or heteroaryl by R, OR, a halogen, preferably F and / or Cl, a CF3, a CN, a N02, a NRR, a C? -6 (saturated), a C6_6 alkoxy, a C3_8 cycloalkoxy, a C3_8 cycloalkyl or a C2_6 alkylene. The term "usal" is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter ion (a cation or anion or is in solution. this is also understood to be complexes of the active compound with other molecules and ions, in particular complexes that are complexed via ionic interactions.The term "physiologically acceptable salt" means in the context of this invention any salt that is physiologically tolerated (most of the time meaning that it is not especially toxic not caused by the counter-ion) is used appropriately for a treatment especially if it is used or applied to humans and / or mammals.These physiologically acceptable salts can be formed with cations or bases and in the context of invention is understood as meaning salts of at least one of the compounds used in according to the invention, usually an (deprotonated) acid - as an anion with at least one cation, preferably organic, which is physiologically tolerated - especially if it is used on humans and / or mammals. The salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH 4, but in particular salts (mono) - or (di) sodium, (mono) - or (di) potassium, magnesium or calcium. These physiologically acceptable salts can be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention usually protonated, for example on nitrogen - to the extent that the cation with at least one anion, which are physiologically tolerated - especially if it is used on humans and / or mammals. This is particularly understood, in the context of the invention, of the salt formed with a physiologically tolerated acid, ie salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if they are used on humans and / or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, or citric acid. The term "solvate" according to this invention should be understood as meaning any form of the active compound according to the invention in which this compound is bound to it by a non-covalent linkage to another molecule (most likely to a solvent polar) which includes especially hydrates and alcoholates, for example methanolate. Unless otherwise stated, the compounds of the invention are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon enriched with 13C- or 14C- or a nitrogen enriched with 15N- are within the scope of this invention. . In a preferred embodiment of the invention for a compound according to formula I at least one of R2, R3 or R4 represent hydrogen, while at least one of R2, R3 or R4 is different from hydrogen.

In a preferred embodiment of the invention for a compound according to formula I R7 represents hydrogen. In a preferred embodiment of the invention for a compound according to formula I R2, R3 and R4 independently of one another represent hydrogen, a linear or branched CX-6 alkyl group, a halogen atom, or CF3, preferably R2, R3 and R4 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the invention for a compound according to formula I R5 and R6 independently of one another represent a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R5 and R6 independently of each other represents methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the invention for a compound according to the formula I R 2 represents a chlorine atom in the 4- position of the phenyl ring, while R 3 and R 4 represent hydrogen. In a preferred embodiment of the invention for a compound according to formula I R5 and R6 each represents chlorine atoms in the 2- and 4- position of the phenyl ring, while R7 represents hydrogen.

In a preferred embodiment of the invention for a compound according to formula I R 1 represents hydrogen, methyl or ethyl, preferably hydrogen.

H In a highly preferred additional aspect of the invention the compound of general formula I is represented by means of a compound of general formula II wherein R 1 represents hydrogen or a linear or branched C 1 _ 4 alkyl group, R 12 or R 13 independently from each other represent a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl , Br and CF3, R14 or R15 independently of one another represent a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02 , SH, NH2, methyl, ethyl, F, Cl, Br and CF3, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, ou n Corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof. In a preferred embodiment of the invention for a compound according to formula II, R12 and R13 independently of one another represent hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R12 and R13 independently one of the other represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the invention for a compound according to formula II R14, and R15 independently from each other represent a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R14 and R15 independently of one of the another represents methyl, ethyl, F, Cl, Br and CF3.

In a preferred embodiment of the invention for a compound according to formula II R 13 represents Cl and R 12 represents hydrogen. In a preferred embodiment of the invention for a compound according to formula II R14 and R15 each represent Cl. In a preferred embodiment of the invention for a compound according to formula II R 1 represents hydrogen, methyl or ethyl, preferably hydrogen. In another preferred embodiment of the compound according to formula I or II is selected from the group consisting of: 5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-lH acid -pyrazol-3-carboxylic acid, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. Another preferred embodiment of the invention also covers any prodrug and compounds of the invention described above as well as any medicament comprising this and any use of these; especially including its esters and ethers. Examples of well-known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found for example in Krogsgaard-Larsen et al. , Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002). Another aspect of the invention is a combination of compounds comprising at least one substituted pyrazoline compound of general formula I wherein R 1 represents hydrogen or a linear or branched C 1 -4 alkyl group, R 2, R 3 and R 4 independently of one another represent hydrogen, a linear or branched C?-6 alkyl group, a linear or branched C?-6 alkoxy group , a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (C = 0) -NHR8 or - (C = 0) -NR8R9 whereby R8 and R9 for each substituent independently represents straight or branched C? E alkyl, R5, R6 and R7 independently of each other represents hydrogen, a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R10 SH, SR10 , SOR10, NH2, NHR10, NR10RX1, ~ (C = 0) -NH2, - (C = 0) -NHR10 and - (C = 0) -? R ^ R11, whereby R10 and optionally R11 for each substituent independently represents linear or branched C? _6 alkyl; Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an α-oxide corresponding thereto, or a corresponding salt thereof, or a corresponding solvate thereof; And at least one substituted pyrazole compound of general formula X Where R16 optionally represents at least one mono-substituted phenyl group, R17 optionally represents at least one mono-substituted phenyl group, R18 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member that it contains a cycloaliphatic group, which can be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which can be condensed with a mono or poly ring system cyclic optionally at least mono substituted, or a portion NR R, R19 and R20, identical or different, represent a hydrogen atom, an aliphatic radical in branched or branched, saturated or unsaturated, optionally at least mono-substituted, a saturated or unsaturated , optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing a straight group aliphatic, which may be condensed with an optionally at least mono-substituted mono or poly cyclic ring system, or an optionally at least mono substituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system optionally at least mono-substituted and / or linked via a linear or branched alkylene group, a -S02-R21 portion, or a NR22 R23 portion, with the proviso that R19 and R20 do not represent hydrogen identically, R21 represents a linear or branched aliphatic group, saturated or unsaturated, optionally at least mono substituted, a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as a ring member containing an aliphatic cycloalkyl group, which may be condensed with a mono or polycyclic ring system, or an optionally at least mono substituted aryl or heteroaryl group, which can be condensed with a mono or polycyclic ring system and / or linked via of a linear or branched alkylene group. R22 and R23, identical or different, represents a hydrogen atom, an unbranched and branched, saturated or unsaturated aliphatic radical, optionally at least mono substituted, a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as a member of ring containing an aliphatic cyclo group, which can be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which can be condensed with a mono-ring system or polycyclic optionally at least mono substituted and / or linked via a linear or branched alkyl group. Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt of these, or a corresponding solvate of these. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I at least one of R 2, R 3 or R 4 represent hydrogen, although at least one R 2, R 3 or R 4 is different from hydrogen. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I at least one of R5, R6 or R7 represent hydrogen, although at least one RB, R6 or R7 is different from hydrogen. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I at least one of R2, R3 and R4 independently of each other represent hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, a CF3, preferably R2, R3 and R4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I R5, R6 and R7 independently of each other represent hydrogen, a linear or branched C? -5 alkyl group, an halogen, or CF3, preferably R5, R6 and R7 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I R2 represents a chlorine atom at the 4-position of the phenyl ring, although R3 and R4 represent hydrogen. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I R5 and R6 each represent a chlorine atom at the 2 and 4 position of the phenyl ring, although R7 represents hydrogen. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I R 1 represent hydrogen, methyl or ethyl, preferably hydrogen.

In a preferred embodiment of the combination of compounds according to the invention, the compound of general formula I is represented by a compound of general formula II H Where R1 represents hydrogen or a linear or branched C? -4 alquilo alkyl group, R 12, R 13, R 14 or R 15 independently of each other represent a linear or branched C? _6 alkyl group, a linear or branched C? _ Alco alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br, and CF3. Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula II R12 and R13 independently of each other represent hydrogen, a linear or branched C? _6 alkyl group, a halogen atom, or CF3, preferably R12 and R13 independently of each other represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula II R 14 and R 15 independently of each other represent hydrogen, a linear or branched C α -6 alkyl group, a halogen atom, or CF3, preferably R14 and R15 independently of each other represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula II R 13 represents Cl and R 12 represents hydrogen. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula II R14 and R15 each represents Cl.

In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula II R 1 represents hydrogen, methyl or ethyl, preferably hydrogen. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula I or II is selected from the group consisting of: 5- (4-chloro-phenyl) -1- (2, 4) -dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid Optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. In a preferred embodiment of the combination of compounds according to the invention for a compound according to the formula X R16 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a C? Alkyl group? Linear or branched _6, a linear or branched C6-alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R ', SH, SR', SOR ', S02R ', NH2, NHR', NR'R ", - (C = 0) -NH2, - (O = 0) -NHR 'and - (C = 0) -NR'R" by means of which R' and R "for each substituent independently represent linear or branched C6-6 alkyl, preferably R16 represents a phenyl group, which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3 more preferably R16 represents a phenyl group, which is mono substituted with a chlorine atom at the 4-position. In a preferred embodiment of the combination of aquatic compounds, The invention relates to a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched C? -6 alkyl group, an alkoxy C group, and ? -6 linear or branched, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R ', SH, SR', SOR ', S02R ', NH2, NHR', NR'R ", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR'R" by means of which R' and optionally R "for each substituent independently represent linear or branched C6-6 alkyl, preferably R17 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3 more preferably R17 represents a phenyl group, which is di substituted with two chlorine atoms in its 2-position A. In a preferred embodiment of the combination of compounds according to the invention for a compound according to formula X R18 represents a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as a ring member containing a C3_8 aliphatic cyclo group, which may be fused with an optionally at least mono substituted mono or polycyclic ring system, or an aryl or 5- or 6-membered heteroaryl optionally at least mono substituted, which may be condensed with an optionally at least mono-substituted mono or polycyclic ring system, or a portion -NR19R20-, preferably R18 represents a saturated, optionally at least mono substituted, optionally one or more nitrogen atoms as ring members containing the C3_8 aliphatic cycle group, which may be condensed with an optionally at least mono-substituted mono or polycyclic ring system, or a -NR19R20- portion, more preferably R18 represent a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, by means of which each of these groups can be substituted with one or more C? _6 alkyl groups, or a -NR18R19 portion. In a preferred embodiment of the combination of compounds according to the invention for a compound according to the formula X R 19 and R 20, which are identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono substituted, a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as a ring member containing a C3-8 cycloaliphatic group / which may be condensed with a mono or polycyclic ring system optionally at least mono-substituted, or a 5- or 6-membered aryl or heteroaryl group optionally at least mono-surtained, which may be condensed with a mono- or polycyclic ring system optionally at least mono-substituted and / or attached via the methylene group ( -CH2-), or ethylene (-CH2-CH-), and a portion S02-R21, or a portion -NR22R23, preferably one of these residues R19 and R20 represent an atom and hydrogen and the other of these residues R19 and R20 represent a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as a ring member containing a C3_8 aliphatic cyclo group, which may be fused to a ring system mono- or polycyclic optionally at least mono-substituted, or an optionally at least mono-substituted 5 or 6-membered aryl or heteroaryl group, which can be condensed with an optionally at least mono-substituted mono or polycyclic ring system, a -S02R21- moiety, or a portion -NR22R23-, or R19 and R20, identical or different, each represents a C? -6 alkyl group, more preferably one of these residues R19 and R20 represent one hydrogen atom and the other of these residues R19 and R20 represent an optionally at least mono substituted pyrrolidinyl group, an optionally at least mono substituted piperidinyl group, an optionally at least mono-substituted piperazinyl group , an optionally at least mono substituted triazolyl group, a -S02-R21, or an -NR22R23, or R19 and R20 portion, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group , a n-butyl group, a sec-butyl group or a tert-butyl group. In a preferred embodiment of the combination of compounds according to the invention for a compound according to the formula X R21 represents a linear or branched C? ~ 6 aliphatic group, saturated or unsaturated, optionally at least mono substituted, a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as a ring member containing a C3_8 aliphatic cyclic group, which may be condensed with a mono ring system or polycyclic, or an optionally at least mono substituted aryl or heteroaryl group of 5 or 6 membered, which can be condensed with a mono or polycyclic ring system and / or linked via a methylene group (-CH2-) or ethylene (-CH2-CH2-), preferably R21 represents a C6 alkyl group, a saturated aliphatic cycloaliphatic group, optionally at least mono substituted, which can be condensed with a mono or polycyclic ring system, or a phenyl group, which is optionally substituted with one or more C? -6 alkyl groups. In a preferred embodiment of the combination of compounds according to the invention for a compound according to the formula X R22 and R23, identical or different, represents a hydrogen atom, an unsaturated or branched, saturated or unsaturated aliphatic radical. unsaturated, optionally at least mono substituted, a saturated or unsaturated, optionally at least mono substituted, optionally at least one heteroatom as ring member containing a C3_8 aliphatic cyclic group, which may be condensed with a mono or polycyclic ring system optionally at less mono substituted, or an optionally at least mono substituted aryl or heteroaryl group of 5 or 6 members, which may be condensed with a mono- or polycyclic ring system optionally at least mono substituted and / or linked via a methylene group (- CH2-) or ethylene (-CH2-CH2-), preferably R22 and R23, identical or different, represent a hydrogen atom or an alkyl radical C? _e, In a Preferred embodiment of the combination of compounds according to the invention The compound according to the general formula X is represented by means of a structure wherein R 16 represents a phenyl ring, which is mono substituted with a halogen atom, preferably an atom of chlorine, in its 4-position, R17 represents a phenyl ring, which is di substituted with two halogen atoms, preferably chlorine atoms, in its 2 and 4 position, R18 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group , a homopiperazinyl group, a morpholinyl group, or a portion -NR19R20, R19 represents a hydrogen atom or a linear or branched C6-6 alkyl group, R20 represents a linear or branched C-6 alkyl group, a -S02R21 portion, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, by means of which each of the heterocyclic rings can be R 2 represents a phenyl group, which is optionally substituted with one or more C 6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers , preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt of these, or a corresponding solvate of these. In a preferred embodiment of the combination of compounds according to the invention the combination of compounds comprises at least one compound according to formula X selected from the group consisting of: N-piperidinyl-5- (4-chloro-phenyl) - 1- (2,4-Dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carboxamide, [1,4] -thirazol-4-yl-amide of 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid, - (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid (4-methyl-piperazin-1-yl) -amide. , - (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid diethylamine, [5- (4-Chloro-phenyl) - l- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-yl] -piperidine-1-yl-methanone, N- [5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carbonyl] -4-methylphenylsulfonamide, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. In a preferred embodiment of the combination of compounds according to the invention the combination of compounds comprises at least one compound according to formula X selected from 5- (4-Chloro-phenyl) -1- (2,4-dichlorophenyl) acid ) -4,5-dihydro-lH-pyrazole-3-carboxylic acid, and N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole -3-carboxamide; Each optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. In another aspect the present invention also provides a process for the preparation of substituted pyrazoline compounds of general formula I or II, wherein R 1 is hydrogen, given above, in which at least one benzaldehyde compound of general formula (III) (III) Where R2, R3 and R4 have the meaning mentioned above, reacts with a pyruvate compound of general formula (IV) (IV) Where G represents an OR group with R being a branched or unbranched C6-6 alkyl radical or G represents an OK group with K being a cation, preferably an anorganic cation, more preferably an alkali metal cation, more preferably sodium, for production of compound of general formula (V) (V) Which is optionally isolated and / or optionally purified, and which reacts with an optionally substituted phenyl hydrazine of general formula (VI) Or a corresponding salt thereof, wherein R5, R and R have the meaning mentioned above, under the inert atmosphere, to produce a compound of general formula (VII) (VII) Wherein R2, R3, R4, R5, R6 and R7 have the meaning given above, which is optionally isolated and / or optionally purified, and optionally esterified with an alkyl ester if it is in the substituted pyrazoline compound of general formula I or II according to the invention R1 is a linear or branched C? _4 alkyl group. The process of the invention is also illustrated in scheme I given above: Esguema I: The reaction of the benzaldehyde compound of general formula III with a pyruvate compound of general formula IV is preferably carried out in the presence of at least one base, more preferably in the presence of an alkali metal hydroxide such as sodium hydroxide or sodium hydroxide. potassium or an alkali metal methoxide such as sodium methoxide, as described, for example, in Synthetic Communications, 26 (11), 2229-33, (1996). The respective description is incorporated herein by reference and forms part of the description. Preferably said reaction is carried out in a protic reaction medium such as an alkyl C 1-4 alkyl alcohol or mixtures thereof. The reaction temperature as well as the duration of the reaction can vary over a wide range. Preferred reaction temperatures range from -10 ° C to the boiling point of the reaction medium. Suitable reaction times may vary, for example, from several minutes or several hours. Also preferred is the reaction of the benzaldehyde compound of the general formula III with a pyruvate compound of the general formula IV is carried out under acid catalyzed conditions, more preferably upon refluxing the mixture in dichloromethane in the presence of copper (II) trifluoromentanesulfonate as described, for example, in Synlett, (1), 147-149, 2001. The respective description is incorporated herein by reference and forms part of the description. The reaction of the compound of general formula (V) with an optionally substituted phenyl hydrazine of general formula (VI) is preferably carried out in a suitable reaction medium such as C?. 4 alcohols or ethers such as dioxane or tetrahydrofuran or mixtures thereof. at least two of these aforementioned compounds. Also preferably, said reaction can be carried out in the presence of an acid, by means of which the acid can be organic such as acetic and / or inorganic acid such as hydrochloric acid. Additionally the reaction can be carried out in the presence of a base such as piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, or a mixture of at least two of these bases can also be used. . The reaction temperature as well as the duration of the reaction can vary over a wide range. Suitable reaction temperatures vary from room temperature, ie about 25 ° C to the boiling point of the reaction medium. Suitable reaction times may vary, for example, from several minutes to several hours. The carboxylic group of the compound of general formula (VII) can be activated for further reactions by the introduction of a suitable leaving group according to conventional methods well known to those skilled in the art. Preferably the compounds of general formula (VII) are transferred in an acid chloride, an acid anhydride, a mixed anhydride, a C? -4 alkyl ester, an activated ester such as p-nitrophenylester. Other well-known methods for activating the acids include activation with N, N-dicyclohexylcarbodiimide or benzotriazole-N-oxotris (dimethylamino) phosphonium hexafluorophosphate (BOP)).

If said activated compound of general formula (VII) is an acid chloride, it is preferably prepared by reaction of the corresponding acid of general formula (VII) with thionyl chloride or oxalyl chloride, by means of which said chlorinating agent is also used as the solvent Also preferably an additional solvent may be used. Suitable solvents include hydrocarbons such as benzene, toluene or xylene, halogenated hydrocarbons such as dichloromethane, chloroform or carbon tetrachloride, ethers such as diethyl ether, dioxane, tetrahydrofuran or dimethyoxyethane. Mixtures of two or more solvents of a class of two or more solvents of different kinds can also be used. The preferred reaction temperature ranges from 0 ° C to the boiling point of the solvent and the reaction times from several minutes to several hours. If said activated compound of general formula (VII) is a mixed anhydride, said anhydride can be preferably prepared, for example, by reaction of the corresponding acid of general formula (VII) with ethyl chloroformate in the presence of a base such as triethylamine or pyridine. , in a suitable solvent. After the activated compound can react with an alkyl alcohol to arrive at the compounds according to the general formulas I or II with R 1 being a linear or branched C 1 -4 alkyl group. During the process described above, the protection of sensitive groups or reagents may be necessary and / or desirable. The introduction of conventional protecting groups as well as their removal can be developed by methods well known to those skilled in the art. If the substituted pyrazoline compounds of the general formula I or II themselves are obtained in the form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures can be separated by standard procedures known to those skilled in the art, chromatographic methods or crystallization. fractionated with chiral reagents. It is also possible to obtain pure stereoisomers by selective stereo synthesis. In a further aspect of the present invention it also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula I or II and stereoisomers thereof, wherein at least one compound of general formula I or II having at least one The basic group reacts with at least one inorganic and / or organic acid, preferably in the presence of a suitable reaction medium. The suitable reaction medium includes, for example, any of those given above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids are for example citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphorsulfonic acid. In still a further aspect of the present dimension there is also provided a process for the preparation of salts of substituted pyrazoline compounds of general formula I or II or stereoisomers thereof, wherein at least one compound of general formula I or II having the less an acidic group reacts with one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are, for example, hydroxides, carbonates or alkoxides, including suitable cations, derived, for example, from alkali metals, alkaline earth metals or organic cations, for example.

[NHnR4_n] +, wherein n is O, 1, 2, 3 or 4 and R represents a C?-Branched or unbranched alkyl radical. Suitable reaction media are, for example, any of those given above. The solvates, preferably hydrates, of the substituted pyrazoline compounds of general formula I or II, of the corresponding stereoisomers, of the corresponding N-oxides or of the corresponding salts thereof can be obtained by standard procedures known to those skilled in the art. . The substituted pyrazoline compounds of general formula I or II, which comprise saturated, unsaturated or aromatic rings containing nitrogen atoms can also be obtained in the form of their N-oxides by methods well known to those skilled in the art. The purification and isolation of the substituted pyrazoline compounds of general formula I or II, of a corresponding stereo isomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art. in the art, for example chromatographic methods or recrystallization. The substituted pyrazoline compounds of general formula I or II given below, their stereoisomers, corresponding N-oxides, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutically active substances for the preparation of medicaments. It has been found that the substituted pyrazoline compounds of general formula (I) and (II) given below, the stereoisomers thereof, the N-oxides thereof, the corresponding salts and the corresponding solvates have the property of regulating the triglyceride levels. in the blood plasma. The combination of the compounds comprises substituted pyrazoline compounds of general formula (I) and (II) given below, their stereoisomers, the corresponding N-oxides, the corresponding salts thereof and the corresponding solvates and the substituted pyrazoline compounds of the formula (X) given below, their stereoisomers, the corresponding N-oxides, the corresponding salts thereof and the corresponding solvates are toxicologically acceptable and are therefore suitable as active pharmaceutical substances for the preparation of medicaments. It has been found that the substituted pyrazoline compounds of general formula X given below, the stereoisomers thereof, the N-oxides thereof, the corresponding salts and the corresponding solvates have high affinity to the cannabinoid receptors, particularly the cannabinoid (CBx) receptors. 1, that is, they act as antagonists on these receptors. Particulate remains of pyrazoline exhibit little or no development of tolerance during treatment particularly with respect to food intake. After finishing the treatment with the pyrazoline compounds, a reduced increase in body weight is found compared to the level of pre-treatment. Thus, another aspect of the present invention relates to a medicament comprising at least one substituted pyrazoline compound of general formula I or II according to the invention and optionally one or more pharmaceutically acceptable excipients. Thus, another aspect of the present invention relates to a medicament comprising at least one substituted pyrazoline compound of general formula I Where R1 represents hydrogen or a linear or branched C4-4 alkyl group, R2, R3 and R4 independently of each other represent hydrogen, a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom CH2F, CHF2, CF3, CN, OH, N02, - (OO) -R8, SH, SR8, SOR8, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (0 = 0) -NHR8 or - (C = 0) -NR8R9 by means of which R8 and R9 for each substituent independently represent straight or branched C6-6 alkyl, R5, R6 and R7 independently of each other represent hydrogen, an alkyl group C ? -6 linear or branched, a linear or branched C? -6 alkoxy group, a halogen atom CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R10, SH, SR10, SOR10, NH2 , NHR10, NR10R1: L, - (C = 0) -NH2, - (C = 0) -NHR10 and - (C = 0) -NR10R1: L, whereby R10 and optionally R11 for each substituent independently represent alkyl Linear or branched C? _6; Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding thereto, or a corresponding salt thereof, or a corresponding solvate thereof; and optionally one or more pharmaceutically acceptable excipients.

In one embodiment of the medicament according to the invention for the compound according to formula I at least one of R2, R3 or R4 represents hydrogen, while at least one of R2, R3 or R4 is different from hydrogen. In one embodiment of the medicament according to the invention for the compound according to formula I at least one of R5, R6 or R7 represents hydrogen, while at least one of R5, R6 or R7 is different from hydrogen. In one embodiment of the medicament according to the invention for the compound according to formula I R2, R3 and R4 independently of each other represent hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3 , preferably R2, R3 and R4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. In one embodiment of the medicament according to the invention for the compound according to formula I R5, R5 and R7 independently of each other represent hydrogen, a linear or branched C6 alkyl group, a halogen atom or CF3, preferably R5, R6 and R7 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. In one embodiment of the medicament according to the invention for the compound according to the formula I R2 represents a chlorine atom at the 4-position of the phenyl ring, while R3 and R4 represent hydrogen. In one embodiment of the medicament according to the invention for the compound according to formula I R5 and R6 each represent chlorine atoms at the 2 and 4 position of the phenyl ring, while R7 represents hydrogen. In one embodiment of the medicament according to the invention for the compound according to formula I R 1 represents hydrogen, methyl or ethyl, preferably hydrogen. In one embodiment of the medicament according to the invention, the compound according to formula I is represented by means of a compound of general formula (II) II Where R 1 represents hydrogen or a linear or branched C 1-4 alkyl group, R 12, R 13, R 14 or R 15 independently of each other represent a linear or branched C? -6 alkyl group, a linear C? -6 alkoxy group or branched, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br, and CF3. Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding of these, or a corresponding salt thereof, or a corresponding solvate thereof. In one embodiment of the medicament according to the invention for the compound according to formula II R 12 and R 13 independently of each other represent hydrogen, a linear or branched C 1-6 alkyl group, a halogen atom, or CF 3 preferably R 12 and R13 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. In one embodiment of the medicament according to the invention for the compound according to formula II R 13 represents Cl and R 12 represents hydrogen.

In one embodiment of the medicament according to the invention for the compound according to formula II R14 and R15 each represent Cl. In one embodiment of the medicament according to the invention for the compound according to formula II R 1 represents hydrogen, methyl or ethyl, preferably hydrogen. In one embodiment of the medicament according to the invention, the compound according to formula I or ll is selected from the group consisting of: 5 - (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4, 5-dihydro-lH-pyrazole-3-carboxylic acid Optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. Another aspect of the invention is a medicament comprising at least one combination of compounds according to the invention and optionally one or more pharmaceutically acceptable excipients. In a medicament modality according to the invention, the medicament is for the regulation of triglyceride levels in the blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, of disorders of the cardiovascular system and of eating disorders, preferably bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. In one embodiment, the medicament comprising the compound according to formula I or II according to the invention, the medicament is for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, gastrointestinal tract disorders or reproductive disorders. In one embodiment, the medicament comprising the combination according to the invention is for the modulation of cannabinoid receptors, preferably cannabinoid receptors 1 (CBX), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system. , disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. In one embodiment of the medicaments according to the invention, the medicament is for the prophylaxis and / or treatment of eating disorders, preferably bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin). ), preferably obesity. In one embodiment of the medicaments according to the invention, the medicament is for the prophylaxis and / or treatment of psychosis. In one embodiment of the medicaments according to the invention the medicament is for the prophylaxis and / or the treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, drug abuse and / or addiction and / or abuse of medication and / or addiction, preferably drug abuse and / or addiction and / or nicotine abuse and / or addiction. In one embodiment of the medicaments according to the invention, the medicament is for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, hawthorn disorders. cerebellar, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbos Alzheimer, Raynaud disease, disorders "tremors", compulsive disorders, senile dementia, chemical disorders, tardive dyskinesia, bipolar disorders; bone disorders including osteoporosis or Paget's bone disease; cancer, preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer , bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer; movement disorders induced by medication, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic analgesics and no narcotics, or to influence intestinal transit. Said medicaments may also comprise any combination of one or more of the substituted pyrazoline compounds of the general formula I given above, the stereoisomers thereof, the corresponding N-oxides thereof, the physiologically acceptable salts thereof or the physiologically acceptable solvates of the latter. these.

Particularly preferably said medicaments are suitable for the prophylaxis and / or treatment of alcohol abuse, drug abuse and / or drug abuse, preferably drug abuse and obesity treatment. Medications and / or drugs, which are frequently the subject of misuse, include opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens, and benzodiazepines. The medicament according to the present invention may be any form suitable for application to humans and / or animals, preferably humans including infants, children and adults and may be produced by standard procedures known to those skilled in the art. The composition of the medication may vary depending on the route of administration. The medicament of the present invention can, for example, be administered parenterally in combination with conventional injectable liquid carriers, such as water or suitable alcohols. Conventional pharmaceutical excipients for injection, such as stabilizing agents, solubilizing agents, and buffers may be included in such injectable compositions. These drugs can, for example, be injected intramuscularly, intraperitoneally, or intravenously. Solid oral compositions (which are preferred as liquid waves) can be prepared by conventional methods of mixing, filling or forming a tablet. Repeated mixing operations can be used to distribute the active agent through those compositions that employ large amounts of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The aforementioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and United States pharmacopoeias and similar reference texts. Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants and acceptable wetting agents. The compositions may take any convenient form, such as tablets, lozenges, capsules, (diamonds), aqueous and oily solutions, suspensions, emulsions, or dry powder forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or delayed release. Oral liquid forms for administration may also contain certain additives such as sweeteners, flavors, preservatives, and emulsifying agents. Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Said liquid compositions may conveniently be encapsulated in, for example, gelatin capsules in a unit dose amount. The compositions of the present invention can also be administered topically or via a suppository. The daily dose for humans and animals can vary depending on factors that are based on respective species or other factors, such as age, sex, weight or degree of disease and so on. The daily dose for humans may preferably be in the range from 1 to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.

Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or II according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, of disorders of the cardiovascular system and disorders of food intake, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or II according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for prophylaxis and / or the treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.

Another preferred aspect of the invention is the use of at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the modulation of cannabinoid receptors, preferably cannabinoid receptors 1 ( CBx), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or II according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and / or treatment of eating disorders, preferably bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or II according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and / or treatment of psychosis. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or II according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and / or treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, drug abuse and / or addiction, and / or drug abuse and / or addiction, preferably drug abuse and / or nicotine addiction or abuse and / or addiction. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I or II according to the invention or at least one combination of compounds according to the invention (and optionally one or more pharmaceutically acceptable excipients), for the preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, seizures, panic, peripheral neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzaimer, Raynaud's disease, tremor disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders; bone disorders that include osteoporosis or Paget's disease of the bone; cancer, preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer , bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, most preferably for prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer; drug-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic analgesics and no narcotics, or to influence intestinal transit.

Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of general formula I Where R1 represents hydrogen or a linear or branched C4-4 alkyl group, R2, R3 and R4 independently of each other represent hydrogen, a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR8, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (0 = 0) -NHR8 O - (0 = 0) -NR8R9 by means of which R8 and R9 for each substituent independently represent linear or branched C6-6 alkyl, R5, R6 and R7 independently of each other represent hydrogen, a group linear or branched C6-6 alkyl, a linear or branched C6-6 alkoxy group, a halogen atom CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R10, SH, SR10, SOR10, NH2, NHR10, NR ^ R11, - (C = 0) -NH2, - (C = 0) -NHR10 and - (C = 0) -NR10R1: L, by means of which R10 and optionally R11 for each substituent independently represent linear or branched C? _6 alkyl; Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding thereto, or a corresponding salt thereof, or a corresponding solvate thereof; and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, of disorders of the system cardiovascular and eating disorders, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes.

Another preferred aspect of the invention is the use for the manufacture of a medicament of at least one substituted pyrazoline compound of formula I for which at least one of R2, R3 or R4 represents hydrogen, although at least one of R2, R3 or R4 is different from hydrogen for the preparation of a medicament for the regulation of triglyceride levels in blood plasma, and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, of disorders of the cardiovascular system and of eating disorders, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which at least one of R5, R6 or R7 represents hydrogen, although at least one R5, R6 or R7 is different from hydrogen for the preparation of a medicine for the regulation of triglyceride levels in blood plasma, and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, disorders of the cardiovascular system and disorders of food intake , especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 2, R 3 and R 4 independently of each other represent hydrogen, a linear or branched C 1-6 alkyl group, a halogen atom or CF3, preferably R2, R3 and R4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3 for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for prophylaxis and / or the treatment of disorders of the central nervous system, especially attacks, disorders of the cardiovascular system and eating disorders, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R5, R6 and R7 independently of each other represent hydrogen, a linear or branched C6-6 alkyl group, an halogen or CF3, preferably R5, R6 and R7 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3 for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for prophylaxis and / or the treatment of disorders of the central nervous system, especially attacks, of disorders of the cardiovascular system and of eating disorders, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R2 represents a chlorine atom in the 4-position of the phenyl ring, while R3 and R4 represent hydrogen for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, disorders of the cardiovascular system and disorders of food intake, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R5 and R6 each represent chlorine atoms in the 2 and 4 position of the phenyl ring, while R7 represents hydrogen for the development of a medicine for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, disorders of the cardiovascular system and disorders of food intake , especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula I for which R 1 represents hydrogen, methyl or ethyl, preferably hydrogen for the manufacture of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of central nervous system disorders, especially attacks, disorders of the cardiovascular system and disorders of food intake, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes non-insulin-dependent mellitus), preferably obesity and diabetes.

Another preferred aspect of the invention is the use of at least one substituted pyrazoline compound of formula wherein the compound of general formula (I) is represented by means of a compound of general formula (II) II Where R 1 represents hydrogen or a linear or branched C 1 _ 4 alkyl group, R 12, R 13, R 14 or R 15 independently of each other represent a linear or branched C 1 _ 6 alkyl group, a linear or branched C 1 _ 6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br, and CF3.

Optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof. For the preparation of a medicine for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially attacks, of disorders of the cardiovascular system and of disorders of food intake, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another embodiment of the invention is the use of at least one substituted pyrazoline compound of formula II for which R12 and R13 independently of each other represent hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3 preferably R12 and R13 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF3 for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for prophylaxis and / or treatment disorders of the central nervous system disorders, especially attacks, disorders of the cardiovascular system and disorders of food intake, especially bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another embodiment of the invention is the use of at least one substituted pyrazoline compound of formula II for which R 14 and R 15 independently of each other represent hydrogen, a linear or branched C 1-6 alkyl group, a halogen atom, or CF3 preferably R14 and R15 independently of one another represents hydrogen, methyl, ethyl, F, Cl, Br and CF3 for the manufacture of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of disorders in the absorption of food, especially bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another embodiment of the invention is the use of at least one substituted pyrazoline of the compound of formula II for which R13 represents Cl and R12 represents hydrogen for the manufacture of a medicament for the regulation of triglyceride levels in blood plasma and for prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of disorders in the absorption of food, especially bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred embodiment of the invention is the use of at least one substituted pyrazoline of the compound of formula II for which R14 and R15 each represents Cl for the manufacture of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially apoplexy, of disorders of the cardiovascular system and disorders in the absorption of food, especially bulimia, anorexia, caquesia, obesity, type II diabetes mellitus (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another preferred embodiment of the invention is the use of at least one substituted pyrazoline of the compound of formula II for which R 1 represents hydrogen, methyl or ethyl, preferably hydrogen for the manufacture of a medicament for the regulation of triglyceride levels in plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and disorders in the absorption of food, especially bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. Another embodiment of the invention is the use of at least one substituted pyrazoline of the compound of formula I or II for which the compound according to formulas I or II is selected from the group consisting of: 5- (4-chloro- phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid, optionally in the form of a corresponding oxide N, a corresponding salt or a corresponding solvate; for the manufacture of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and of disorders in the absorption of food, especially bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. The present invention is illustrated below with the help of the examples. These illustrations are given by way of example only and are not intended to limit the present invention. Examples: Example 0 represents a compound according to formula I or II. Example 0: 5- (4-Chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxylic acid a) 4- (4-Chlorophenyl) -2-oxo-3-butenoic acid In a three-necked flask p-chlorobenzaldehyde (13.3 g, 95 mmol) and ethyl pyruvate (10 g, 86 mmol) are dissolved in 150 ml of absolute ethanol. The solution is cooled with ice 0o C and an aqueous solution of NAOH (3.8 g in 45 mL of water) is added dropwise to maintain the temperature below or equal to 10 ° C, whereby a colored precipitate is formed yellow orange. The reaction mixture is stirred for 1 hour at 0 ° C and additionally 1.5 hours at room temperature (approximately 25 ° C). The reaction mixture is then cooled to below about 5 ° C and the insoluble sodium salt of 4- (-chlorophenyl) -2-oxo-3-butenoic acid is isolated by filtration. The filtrate is left in the refrigerator overnight, whereby more precipitate forms, which is filtered, combined with the first fraction of the salt and washed with diethyl ether. The sodium salt of 4- (4-chlorophenyl) -2-oxo-3-butenoic acid is then treated with a 2N HCl solution, stirred for a few minutes and the 4- (4-chlorophenyl) -2 acid is separated. -oxo-3-butenoic solid by filtration and dried to give 12.7 g of the desired product (70% theoretical yield).

IR (KBr, cm "" 1): 3500-2500, 1719.3, 1686.5, 1603.4, 1587.8, 1081.9. 2 H NMR (CDC13, d): 7.4 (d, J = 8.4Hz, 2H), 7.5 (d, J = 16, 1Hz, ÍH), 7.6 (d, J = 8.4 Hz , 2H), 8.1 (d, J = 16, l Hz, lH). a2) 5- (4-Chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid In an alternative route, instead of using ethylpiruvate, the CH3-C salt is used ( 0) -C (0) -0"Na + (sodium pyruvate), dissolved in ethanedic water b) 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dxhydro-pyrazole- 3-carboxylic 4- (4-Chlorophenyl) -2-oxo-3-butenoic acid is obtained according to step a) (12.6 g, 60 mmol), 2,4-dichlorophenylhydrazine hydrochloride (12. 8 g, 60 mmol) and Glacial acetic acid (200 mL) is mixed under a nitrogen atmosphere and heated to reflux for 4 hours, cooled below room temperature (approximately 25 ° C) and placed in ice water, whereby a sticky mass is obtained , which is extracted with methylene chloride. The combined methylene chloride fractions are washed with water, dried over sodium sulfate, filtered and evaporated to dryness to give a pale yellow solid (12.7 g, 57% theoretical yield). IR (KBr, cm "1): 3200-2200, 1668.4, 1458, 1251.4, 1104.8.

X H NMR (CDC13, d): 3.3 (dd, 1H), 3.7 (dd, 1H), 5.9 (dd, 1H), 7.09-7.25 (m, 7H). Examples 1 to 6 represent compounds according to formula X. Example 1: N-Piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3 -carboxamide (a) 5- (4-Chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid chloride Under a nitrogen atmosphere, 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid (2.5 g, 6.8 mmol) is obtained according to Example 0 Dissolve in 4 mL of thionyl chloride and heat at reflux for 2.5 hours. Excess thionyl chloride is removed from the reaction mixture under reduced pressure and the resulting crude residue (2.6 g) is used without further purification. IR (KBr, cpf1): 1732.3, 1700.1533.3, 1478.1, 1212.9, 826.6. An agitated compound of these compounds according to the general formulas I and II wherein R 1 is a linear or branched C 1 -4 alkyl group can be prepared by reacting this compound with the appropriate alkyl alcohol. (b) N-Piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide Under a nitrogen atmosphere, N-aminopiperidine (0.6 mL, 5.6 mmol) and triethylamine (4 mL) are dissolved in methylene chloride (25 mL). The resulting mixture is cooled with ice at 0 ° C and a solution of 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid chloride is obtained in the Step (c) is added dropwise to methylene chloride (15 mL). The resulting reaction mixture is stirred at room temperature (approximately 25 ° C) overnight. The reaction mixture is then washed with water, followed by a saturated aqueous sodium bicarbonate solution, then again with water, dried over sodium sulfate, filtered and evaporated to dryness in a rotary evaporator. The resulting crude solid is crystallized from ethanol. The crystallized solid is removed by filtration and the mother liquors are concentrated to produce a second fraction of the crystallized product. The two fractions are combined to give a total amount of 1.7 g (57% theoretical yield) of N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3. -carboxamide having a melting point of 183-186 ° C. IR (KBr, cm "1): 3222.9, 2934.9, 1647.4, 1474.7, 1268.3, 815.6. (CDC13, d): 1.4 (m, 2H), 1.7 (m, 4H), 2.8 (m, 4H), 3.3 (dd, J = 6, 1 and 18.3 Hz, IH), 3.7 (dd, J = 12.5 and 18.3 Hz, ÍH), 5.7 (dd, J = 6, l and 12.5 Hz, ÍH), 7.0-7.2 (m, 6H), 7.4 (Yes H) . The compounds according to the following examples 2-6 have been prepared analogously to the process described in Example 1 in combination with Example 0. Example 2: [1,2,4] riazol-4-yl-amide acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid Melting point: 134-138 ° C.

IR (KBr, cm "1): 3448, 1686, 1477, 1243, 1091, 821. XH NMR (CDC13, d): 3.1 (dd, J = 6.2 and 17.9 Hz, 1H), 3 , 7 (dd, J = 12.3 and 17.9 Hz, HH), 5.9 (dd, J = 6.2 and 12.3 Hz, HH), 7.2-7.5 (m, 7H), 8.7 (s) , 2H), 12.0 (bs, 1H). Example 3: 5- (4-Methyl-piperazin-1-yl) -amide- (4-methyl-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH- hydrochloride pyrazole-3-carboxylic melting point: 150-155 ° C. IR (KBr, cm "1): 3433, 1685, 1477, 1296, 1246, 1088, 1014, 825. 2H NMR (CDC13, d): 2, 7 (d, J = 4.2 Hz, 3H), 3.0-3, 4 (m, 9H), 3. 6 (dd, J = ll, 9 and 17.9 Hz, ÍH), 5.8 (dd, J = 5.5 and 11.9 Hz, ÍH), 7.1 (d, J = 8.4Hz, 2H), 7.25 (2d, J = 8.4 and 8.7 Hz, 3H), 7.4 (d, J = 2.2 Hz, 1H), 7.5 (d, J = 8.7 Hz, ÍH), 9.8 (s, 1H), 11.2 (bs). Example 4: 5- (4-Chloro-phexyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-xiazole-3-carboxylic acid diethylamine This compound is obtained in the form of an oil . IR (film, cm "1): 2974, 1621, 1471, 1274, 1092, 820. XH NMR (CDCl 3, d): 1.2 (m, 6H), 3.3-3.9 (m, 6H) , 5.6 (dd, J = 5.8 and 11.7 Hz, ÍH), 7-7.25 (m, 7H) Example 5: [5- (4-Chloro-phenyl) -1- (2 , 4-dichloro-phenyl) -4,5-dihydro-lH-pyrazol-3-yl] -piperidin-1-yl-methanone Melting point: 105-110 ° C. IR (KBr, cm "1): 2934 , 1622, 1470, 1446, 1266, 1010, 817.

U NMR (CDCl 3, d): 1.7 (m, 6H), 3.4 (dd, J = 5.7 and 17.9Hz, HI), 3.7 (m, 3H), 3.9 (m , 2H), 5.6 (dd, J = 6, l and 11.9 Hz, ÍH), 7-7.25 (m, 7H). Example 6: N- [5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carbonyl] -4-methyl-phenylsulfonamide This compound it is obtained in the form of an amorphous solid. IR (KBr, cm "" 1): 1697, 1481, 1436, 1340, 1169, 1074, 853. XH NMR (CDC13, d): 2.4 (s, 3H), 3.2 (dd, J = 6 , 6 and 18.3Hz, ÍH), 3,6 (dd, J = 12.8 and 18.3Hz, ÍH), 5,8 (dd, J = 6,6 and 12,8Hz, ÍH), 7 ( d, J = 8.2 Hz, 2H), 7.2 (s, ÍH), 7.3-7.4 (m, 6H), 8 (d, J = 8, l Hz, 2H), 9 ( Yes H) . Example 7: N-Piperidinyl-5- (-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide N-oxide. Under nitrogen gas as an inert atmosphere N-piperidinyl- is dissolved. 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide (0.15 g, 332 mmol) in 7 ml of dichloromethane. The resulting solution is cooled with ice at 0 ° C and m-chloroperbenzoic acid (0.204 g, 0.83 mmol) is added in several portions. After stirring for 15 minutes a thin layer chromatography control shows that there is no excess starting material. Then a solution of saturated sodium bicarbonate is added slowlyThe organic phase is separated, washed with water, dried over sodium sulfate and filtered. The filtered solution is evaporated to dryness and the crude product is purified by column chromatography yielding 78 mg (50% of theoretical yield) of N-piperidinyl-5- (4-chlorophenyl) -1- (2, 4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide in the form of a white solid having a melting point of 115-120 ° IR (KBr, cm "1): 3202, 1678, 1654, 1474, 1309, 1107. aH-NMR (CDC13, d): 1.6 (m, 2H), 1.8-2.0 (m, 4H), 2.55 ( m, 2H), 3.3 (dd, J = 6.3 Hz and 18.2 Hz, ÍH), 3.7 (m, 3H), 5.8 (dd, J = 6.3 Hz and 12.5 Hz, ÍH), 7.0-7.3 (m, 7H), 8.5 (s, H). Pharmacological data / Assay The compound according to Example 0 is an inhibitor of high levels of triglycerides in blood. This effect has been proven in obese mice fed a high-fat diet. The method and results obtained in the study are described in the following paragraphs. I. In vivo test for the regulation of triglycerides in blood plasma The study is carried out using six-week-old male B6 Lep ob / ob mice, obtained from Charles River (France). The mice are divided into three groups: I (control), II (vehicle), III (example 0).

Group I: Group I animals receive the standard diet (D-1245OB, Research Diets, NJ, USA). Group II: Animals of groups II and III are fed a High Fat Diet (D-12492, Research Diets, NJ, USA), in both cases for 7 weeks (References 1 and 2). Group III: Animals of groups III are fed a High Fat Diet (D-12492, Research Diets, NJ, USA), in both cases for 7 weeks (References 1 and 2). At the end of the 7-week feeding period, the treatment period starts. (14 days): Group II mice are received vehicle (10 ml / kg / day, po, from the acacia gum aqueous solution, 5% W / V). Group III is administered 30 mg / kg / day, po, of the compound of the invention of 5- (-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid of according to Example 0. Group I does not receive any treatment. At the end of the 14-day treatment period, the triglyceride levels in the blood of the animals are determined. The analysis of the whole blood samples is done using "Lipid Panel" test strips and the Photometric Analyzer Cardio-Check Test System, from PA Instruments Polymer Technology Systems Indianapolis, IN-46268, USA (Distributed in Spain by Novalab Ibérica SA L , Madrid Spain) . The results obtained are the following: * p < 0.05, Anova followed by Bonferroni trial, compared to Group I. NS: there is no significant difference, compared to Group I.

The results show that Group II mice receiving a high-fat diet have significantly higher blood triglyceride levels than Group I control. But administration of the compound according to Example 0 (Group III) improves the levels of triglycerides in the blood, which do not differ from the levels of Group I, which receive the standard diet. Figure 1 shows the clear reduction of triglyceride levels in the blood plasma. The level (Group III) returns to the control level of Group I compared to the clearly high levels found in Group II without the treatment of the compound according to Example o. Thus, the inhibitory effect of the compound of the invention of 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid according to Example 0 has been tested. On the high levels of triglycerides in the blood References l.-Lambert PD et al .. "Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat" PNAS 2001, 28 (8): 4652-4657 2. -Grass MM et al "Oleoyl-Estrone lowens the body weight of both ob / ob and db / db mice, Hozm Metab Res 2000,32: 246-250 II.In vivo test for the regulation of triglycerides in the blood plasma In a second The set of experiments carried out in a similar way to the tests shown above, determine the levels of TG (triglyceride) in blood of obese mice with diet induced.Mice receiving a high-fat diet - after a feeding period of 6 days- they are treated with a vehicle (0.5% HPMC) or with the compound according to Example 0 (30 mg / kg / day p.o.). TG levels in blood are determined on day 28 after starting treatment. The levels of TG (triglycerides) are 1.28 ± 25 mmol / l in the group treated with the vehicle and only 0.80 ± 0.07 mmol / l in the group treated with the compound of the invention 5- (4- chlorophenyl) - 1- (2, 4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid according to Example 0. The results are statistically highly important with a factorial ANOVA, Fishes post-hoc test of *** p <; 0.005 versus vehicle. Thus, the inhibitory effect of the compound of the invention is further demonstrated 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid according to Example 0 about the high levels of triglycerides in the blood.

Claims

CLAIMS 1. Substituted pyrazoline compounds of general formula I, wherein R1 represents hydrogen or a linear or branched C4-4 alkyl group, R2, R3 and R4 independently of one another represents hydrogen, a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, an atom of halogen, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (C = 0) - NHR8 or - (C = 0) -NR8R9 whereby R8 and R9 for each substituent independently represents linear or branched C6-6 alkyl, R5 and R6 independently of one another represents a linear C6.6 alkyl group or branched, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R10, SH, SR10, SOR10, NH2, NHR10, NR10RX1, - (C = 0) -NH2, - (C = 0) -NHR10 and - (C = 0) -NR10R?: L, whereby R10 and optionally R11 for each substituent independently represents linear or branched C? _6 alkyl; R7 represents hydrogen, a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R10, SH, SR10, SOR10, NH2, NHR10, NR10R1: L, - (C = 0) - NH2, - (CAD) -NHR10 and - (C = 0) -NR10R1: 1, whereby R10 and optionally R11 for each substituent independently represents linear or branched C? -6 alkyl; with the proviso that if R1 and R7 are H and R5 and R6 both represent Cl in the 3- and 4- position of the phenyl ring none of R2, R3 and R4 may represent F in the 4- position of the phenyl ring if the two others of R2, R3 and R4 both represent H; optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof.
2. The compounds according to claim 1, characterized in that at least one of R2, R3 or R4 represents hydrogen, while at least one of R2, R3 or R4 is different from hydrogen.
3. The compounds according to any one of claims 1 or 2, characterized in that R7 represents hydrogen.
4. The compounds according to any one of claims 1 to 3, characterized in that R2, R3 and R4 independently of one another represents hydrogen, a linear or branched C?, 6 alkyl group, a halogen atom, or CF3, preferably R2, R3 and R4 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3.
5. The compounds according to any one of claims 1 to 4, characterized in that R5 and R6 independently of one another represents a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R5 and R6 independently one of the other represents methyl, ethyl, F, Cl, Br and CF3.
6. The compounds according to any one of claims 1 to 5, characterized in that R2 represents a chlorine atom in the 4- position of the phenyl ring, while R3 and R4 represents hydrogen. The compounds according to any one of claims 1 to 6, characterized in that R5 and R6 each represent chlorine atoms in the 2- and 4- position of the phenyl ring, while R7 represents hydrogen. 8. The compounds according to any one of claims 1 to 7, characterized in that R1 represents hydrogen, methyl or ethyl, preferably hydrogen. 9. The compounds of general formula II according to one or more of claims 1 to 8 where R1 represents hydrogen or a linear or branched C? -4 alquilo alkyl group, R 12 or R 13 independently of one another represents a linear or branched C? _6 alquilo alkyl group, a linear or branched C?-E alkoxy group, a halogen atom, CH 2 F , CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br and CF3, R14 or R15 independently of one another represents a linear or branched C6-6 alkyl group, a linear C6-alkoxy or branched, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, methyl, ethyl, F, Cl, Br and CF3, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate of these. 10. Compounds according to claim 9 characterized in that R12 and R13 independently of each other represents hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R12 and R13 independently of each other represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. 11. The compounds according to any one of claims 9 or 10, characterized in that R14, and R15 independently of one another represents a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R14 and R15 independently of one another represents methyl, ethyl, F, Cl, Br and CF3. 12. The compounds according to any one of claims 9 to 11, characterized in that R13 represents Cl and R12 represents hydrogen. 13. The compounds according to any one of claims 9 to 12, characterized in that R14 and R15 each represents Cl. 14. The compounds according to any one of claims 9 to 13, characterized in that R1 represents hydrogen, methyl or ethyl, preferably hydrogen. 15. The compounds according to one or more of claims 1 to 14 selected from the group consisting of: 5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro- 1H-pyrazole-3-carboxylic acid, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. 16. The combination of compounds comprises at least one pyrazoline compound of general formula I wherein wherein R1 represents hydrogen or a linear or branched C4 alkyl group, R2, R3 and R4 independently of one another represents hydrogen, a linear or branched C6.6 alkyl group, a linear or branched C6-6 alkoxy group, an atom of halogen, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (0 = 0) - NHR8 or - (0 = 0) -NR8R9 whereby R8 and R9 for each substituent independently represents alkyl Linear or branched C? -6, R5, R6 and R7 independently of one another represents hydrogen, a linear or branched C? _6 alkyl group, a linear or branched C? -6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (0 = 0) -R10 SH, SR10, SOR10, NH2, NHR10, NR ^ R11, - (C = 0) -NH2, - (0 = 0) - NHR10 and - (0 = 0) -NR10R1: L, whereby R10 and optionally R11 for each substituent independently represents linear or branched C? _6 alkyl; optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof; and at least one substituted pyrazoline compound of general formula X X wherein R 16 represents an optionally at least nono-substituted phenyl group, R 17 represents an optionally at least nono-substituted phenyl group, R 18 represents a cycloaliphatic group optionally containing at least one heteroatom as ring member, at least optionally mono-substituted , saturated or unsaturated, which may be optionally condensed with at least one mono-substituted mono or polycyclic ring system, or optionally at least one mono-substituted heteroaryl or aryl group, which may be optionally condensed with at least one mono ring system or mono-substituted polycyclic, or a portion -NR19R20-, R19 and R20, identical or different, represent a hydrogen atom, optionally at least one mono-substituted, saturated or unsaturated, branched or unbranched aliphatic radical, a cycloaliphatic group which optionally contains at least one heteroatom as ring member, at least optionally mono-substituted, saturated or unsaturated which may be optionally condensed with at least one mono-substituted mono or polycyclic ring system, or optionally at least one mono-substituted heteroaryl or aryl group, which may be optionally condensed with at least one mono or polycyclic ring system -substituted and / or linked by a linear or branched alkylene group, a portion -S02-R21-, or a portion -NR22R23-, with the proviso that R19 and R20 identically do not represent hydrogen, R21 optionally represents at least one saturated or unsaturated mono-substituted aliphatic group, linear or branched, a cycloaliphatic group optionally containing at least one heteroatom as an optionally at least mono-substituted, saturated or unsaturated ring member, which may be fused with a mono or polycyclic ring system, or optionally at least one heteroaryl group or mono-substituted aryl, which can be condensed with a mono or polycyclic ring system and / or linked by a linear or branched alkylene group, R22 and 23, identical or different, represent a hydrogen atom, optionally at least one aliphatic radical mono-substituted, saturated or unsaturated, branched or unbranched, a cycloaliphatic group optionally containing at least one heteroatom as ring member, at least optionally mono-substituted, saturated or unsaturated, which may be optionally condensed with at least one system mono- or polycyclic mono-substituted ring, or optionally at least one heteroaryl or mono-substituted aryl group, which may optionally being condensed with at least one mono- or polycyclic ring system mono-substituted and / or linked by a linear or branched alkylene group, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof. 17. The combination of the compounds according to claim 16, characterized in that at least one of R2, R3 or R4 represents hydrogen, while at least one of R2, R3 or R4 is different from hydrogen. 18. The combination of the compounds according to any one of claims 16 or 17, characterized in that at least one of R5, R6 or R7 represents hydrogen, while at least one R5 R6 or R7 is different from hydrogen. 19. The combination of the compounds according to any one of claims 16 to 18, characterized in that R2, R3 and R4 independently of each other represents hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R2, R3 and R4 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. The combination of the compounds according to any one of claims 16 to 19, characterized in that R5, R6 and R7 independently of one another represent hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R5, R6 and R7 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. 21. The combination of the compounds according to any one of claims 16 to 20, characterized in that R2 represents a chlorine atom in the 4- position of the phenyl ring, while R3 and R4 represents hydrogen. 22. The combination of the compounds according to any one of claims 16 to 21, characterized in that R5 and R6 each represent chlorine atoms in the 2- and 4- position of the phenyl ring, while R7 represents hydrogen . 23. The combination of the compounds according to any one of claims 16 to 22, characterized in that R1 represents hydrogen, methyl or ethyl, preferably hydrogen. 24. The combination of the compounds according to any one of claims 16 to 23 characterized in that the compound of general formula I is represented by a compound of general formula II p where R1 represents hydrogen or a linear or branched C? -4 alquilo alkyl group, R 12, R 13, R 14 or R 15 independently of one another represents a linear or branched C? _6 alkyl group, a linear or branched C? _6 alkoxy group, an halogen, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br and CF3, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof. 25. The combination of the compounds according to claim 24 characterized in that R12 and R1 independently of each other represents hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R12 and R13 independently of each other represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. 26. The combination of the compounds according to any one of claims 24 or 25, characterized in that R, and R15 independently of one another represents hydrogen, a linear or branched C? _6 alkyl group, a halogen atom, or CF3 , preferably R14 and R15 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. 27. The combination of the compounds according to any one of claims 24 to 26, characterized in that R13 represents Cl and R12 represents hydrogen. 28. The combination of the compounds according to any one of claims 24 to 27, characterized in that R14 and R15 each represent Cl. 29. The combination of the compounds according to any one of claims 24 to 28, characterized in that R 1 represents hydrogen, methyl or ethyl, preferably hydrogen. 30. The combination of the compounds according to one or more of claims 16 to 29 characterized in that the compound according to formula I or II is selected from the group consisting of: 5- (4-chloro-phenyl) acid -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. 31. The combination of the compounds according to any one of claims 16 to 30, characterized in that R16 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a C? 6 linear or branched, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02 / - (0 = 0) -R ', SH, SR', SOR ', S02R ', NH2, NHR', NR'R ", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR'R" whereby R' and R '' for each substituent independently represents straight or branched C6-6 alkyl, preferably R16 represents a phenyl group, which is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R16 represents a phenyl group, which is mono-substituted with a chlorine atom in the 4-, position 32. The combination of the compounds according to any one of the claims 16 to 31, characterized in that R17 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C6-6 alkoyl group, a straight or branched C6 alkoxy group, an atom of halogen, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R ', SH, SR', SOR ', S02R', NH2, NHR ', NR'R', - (C = 0) -NH2 / - (C = 0) -NHR 'and - (C = 0) -NRR ", whereby R' and optionally R" for each substituent independently represents linear or branched C? _6 alkyl, preferably R17 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R17 represents a phenyl group, which is di-substituted with two chlorine atoms in their positions 2- and 4-. 33. The combination of the compounds according to one or more of claims 16 to 32, characterized in that R18 represents a C3-8 cycloaliphatic group optionally containing at least one heteroatom as an optionally at least mono-substituted, saturated or unsaturated ring member , which may be optionally condensed with at least one monosubstituted mono or polycyclic ring system, or a 5- or 6-membered heteroaryl or aryl group, optionally at least mono-substituted, which may be optionally condensed with at least one Mono-substituted mono or polycyclic ring system, or a portion NR19R20-, preferably R18 represents a C3-8 cycloaliphatic group optionally containing at least one or more nitrogen atoms as optionally at least mono-substituted, saturated or unsaturated ring members , which can be condensed with a mono- or polycyclic ring system optionally at least mono-substituted, or a portion -R19R20-, more pre preferably R18 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, whereby each of these groups can be substituted with one or more alkyl groups Ca-6, or a portion of -NR18R19-. 34. The combination of the compounds according to one or more of claims 16-33, characterized in that R19 and R20, identical or different, represent a hydrogen atom, an aliphatic radical C? _6 optionally at least mono-substituted, saturated or unsaturated, branched or unbranched, a C3_8 cycloalkyl group optionally containing at least one heteroatom as ring member, optionally at least saturated or unsaturated mono-substituted, which may be optionally condensed with at least one mono or polycyclic ring system substituted, or a 5- or 6-membered heteroaryl or aryl group, optionally at least mono-substituted, which may be optionally condensed with at least one mono- or polycyclic ring system mono-substituted and / or linked by a methylene group (-CH2-) or ethylene (-CH2-CH2) -, a portion -S02-R21-, or a portion -NR22R23-, preferably one of these residues R9 and R20 represents a hydrogen atom and the other of these residues R19 and R20 represents a C3-8 cycloalkyl group optionally containing at least one heteroatom as ring member, optionally at least mono-substituted saturated or unsaturated, which may be optionally condensed with at least one mono-substituted polycyclic ring system, or a 5- or 6-membered heteroaryl or aryl group, optionally at least mono-substituted, which may be optionally condensed with at least one mono- or polycyclic ring system, one -SO-R21- portion, or one portion - NR22R23 -, or R19 and R20, identical or different, each represents a C? -6 alkyl group, more preferably one of these residues R19 and R20 represents a hydrogen atom and the other of these residues R19 and R20 represents a pyrrolidinyl group optionally at least mono-sust an optionally at least mono-substituted piperidinyl group, an optionally at least mono-substituted piperazinyl group, an optionally at least mono-substituted triazolyl group, a S02-R2- moiety, or a -NR22R23- moiety, or R19 and R20 , identical or different, represents a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tert-butyl group. 35. The combination of the compounds according to one or more of claims 16-34, characterized in that R21 represents an optionally at least mono-substituted, saturated or unsaturated, linear or branched aliphatic group C? _6, an aliphatic group C Optionally at least mono-substituted, saturated or unsaturated, linear or branched a C3_8 cycloaliphatic group optionally containing at least one heteroatom as ring member, optionally at least mono-substituted, saturated or unsaturated, which may be condensed with a mono or polycyclic ring systemor a 5- or 6-membered heteroaryl or aryl group, optionally at least mono-substituted, which can be condensed with a mono- or polycyclic ring system and / or linked by a methylene group (-CH 2 -) or ethylene ( -CH2- CH2) -, preferably R21 represents a C6_6 alkyl group, an optionally at least mono-substituted, saturated or unsaturated cycloaliphatic group, which may be condensed with a mono- or polycyclic ring system, or a phenyl group, which is optionally substituted with one or more C? _6 alkyl groups. 36. The combination of the compounds according to one or more of claims 16-35, characterized in that R22 and 23, identical or different, represent a hydrogen atom, an optionally at least mono-substituted C6-aliphatic radical. , saturated or unsaturated, branched or unbranched, a C3-.8 cycloaliphatic group optionally containing at least one heteroatom as an optionally at least mono-substituted, saturated or unsaturated ring member, which may be optionally condensed with at least one mono- or polycyclic mono-substituted ring, or a 5- or 6-membered heteroaryl or aryl group, optionally at least mono-substituted, which may be optionally condensed with at least one monosubstituted mono- or polycyclic ring system and / or linked by a methylene (-CH-) or ethylene (-CH2-CH2) -, preferably R22 and 23, identical or different group, represent a hydrogen atom or a C? _6 alkyl radical. 37. The combination of the compounds according to any one of claims 16 to 36 characterized in that the compound according to the general formula X is represented by a structure wherein R16 represents a phenyl ring, which is mono-substituted with a halogen atom, preferably a chlorine atom, in its 4- position, R17 represents a phenyl ring, which is di-substituted with two halogen atoms, preferably chlorine atoms, in its 2- and 4- position, R 18 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, or a -R19R20- portion, R19 represents a hydrogen atom or a linear or branched alkyl group, R20 represents a linear alkyl group or branched, a -S02-R21-, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homopiperazinyl group, a morpholinyl group, a triazolyl group, therefore each of the rings Eterocyclics can be substituted with one or more, identical or different, C6 alkyl groups, and R21 represents a phenyl group, which is optionally substituted with one or more C6-6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt of these, or a corresponding solvate of these. 38. The combination of the compounds according to one or more of claims 16 to 37, characterized in that they comprise at least one compound according to formula X selected from the group consisting of: N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carboxamide, [1,2,4] -triazole-4-acid 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid (4-methyl-piperazine-1-yl) -yl) -amide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid, Diethylamine of 5- (4-chloro) phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid, [5- (4-chloro-phenyl) -1- (2,4-dichloro- phenyl) -4,5-dihydro-lH-pyrazol-3-yl] -piperidine-1-yl-methanone, N- [5- (4-chloro-phenyl) -1- (2, -dichlorophenyl) -4, 5-dihydro-lH-pyrazole-3-carbonyl] -4-methylphenylsulfonamide, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. 39. The combination of the compounds according to one or more of claims 16 to 38, characterized in that it comprises at least 5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5 acid. -dihydro-1H-pyrazole-3-carboxylic acid, and N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carboxamide; Each optionally in the form of a corresponding oxide N, a corresponding salt or a corresponding solvate, 40. A process for the manufacture of substituted pyrazoline compounds of general formula I or II, wherein R 1 is hydrogen, in accordance with one or more of claims 1 to 15, characterized in that at least one benzaldehyde compound of general formula III IU) wherein R, R3 and R4 has the meaning according to one or more of claims 1-8, it reacts with a pyruvate compound of general formula (IV) wherein G represents an OR group with R being a branched or unbranched C6-6 alkyl radical or G represents a group 0"K with K being a cation, to produce a compound of general formula (V) which is optionally isolated and / or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of general formula (VI) (VI) or a corresponding salt thereof, wherein R 5, R 6 and R 7 have the meaning according to one or more of claims 1-8, under an inert atmosphere, to produce a compound of general formula (VII) W§ wherein R2, R3, R4, R5, R6 and R7 have the meaning as given above, which is optionally isolated and / or optionally purified, and optionally esterified with an alkyl ester if in the substituted pyrazoline compound of general formula I according to one or more of claims 1 to 15 R1 is a linear or branched C6 alkyl group. 41. The medicament comprises at least one substituted pyrazoline compound of general formula I or II according to one or more of claims 1 to 15, and optionally one or more pharmaceutically acceptable excipients. 42. The medicament comprises at least one substituted pyrazoline compound of general formula I wherein R 'represents hydrogen or a linear or wherein R1 represents hydrogen or a linear or branched C? -4 alquilo alkyl group, R 2, R 3 and R 4 independently of one another represents hydrogen, a linear or branched C?-6 alkyl group, a linear or branched C?-6 alkoxy group , a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (0 = 0) - NHR8 or - (C = 0) -NR8R9 whereby R8 and R9 for each substituent independently represents alkyl Linear or branched C-6, R5 and R6 independently of one another represents a linear or branched C6-6 alkyl group, a linear or branched C6-alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH , N02 / - (0 = 0) -R10, SH, SR10, SOR10, NH2, NHR10, NR10R1: L, - (C = 0) -NH2, - (0 = 0) -NHR10 and - (0 = 0) -NR10R1: L, whereby R10 and optionally R11 for each substituent independently represents linear or branched C? -6 alkyl; optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof. optionally one or more pharmaceutically acceptable excipients. 43. The medicament according to claim 42, characterized in that at least one of R2, R3 or R4 represents hydrogen, while at least one of R2, R3 or R4 is different from hydrogen. 44. The medicament according to any one of claims 42 or 43, characterized in that at least one of R5, R6 or R7 represents hydrogen, while at least one of R5, R6 or R7 is different from hydrogen. 45. The medicament according to any one of claims 42 to 44, characterized in that R2, R3 and R4 independently of one another represents hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R2, R3 and R4 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. 46. The medicament according to any one of claims 42 to 45, characterized in that R5, R6 and R7 independently of one another represent hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3 , preferably R5, R6 and R7 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. 47. The medicament according to any one of claims 42 to 46, characterized in that R2 represents a chlorine atom in the 4- position of the phenyl ring, while R3 and R4 represents hydrogen. 48. The medicament according to any one of claims 42 to 47, characterized in that R5 and R6 each represent chlorine atoms in the 2- and 4- position of the phenyl ring, while R7 represents hydrogen. 49. The medicament according to any one of claims 42 to 48, characterized in that R1 represents hydrogen, methyl or ethyl, preferably hydrogen. 50. The medicament according to one or more of claims 42 to 49 characterized in that the compound of general formula (I) is represented by a compound of general formula (II) H wherein R1 represents hydrogen or a linear or branched C6-6 alkyl group, R12, R13, R14 or R15 independently of one another represents a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br and CF3, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate of these. 51. The medicament according to claim 50 characterized in that R12 and R13 independently of each other represents hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R12 and R13 independently of each other represents hydrogen , methyl, ethyl, F, Cl, Br and CF3. 52. The medicament according to any one of claims 50 or 51, characterized in that R14, and R15 independently of one another represents hydrogen, a linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R14. and R15 independently of one another represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. 53. The medicament according to any one of claims 50 to 52, characterized in that R13 represents Cl and R12 represents hydrogen. 54. The medicament according to any one of claims 50 to 53, characterized in that R14 and R15 each represents Cl. 55. The medicament according to any one of claims 50 to 54, characterized in that R1 represents hydrogen, methyl or ethyl, preferably hydrogen. 56. The medicament according to one or more of claims 42 to 55 characterized in that the compound according to the formulas I or II is selected from the group consisting of: 5- (4-chloro-phenyl) -1- (2 , 4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. 57. The medicament comprising at least one of the combinations of the compounds according to one or more of claims 16 to 39 and optionally one or more pharmaceutically acceptable excipients. 58. The medicament according to claim 42 to 57 for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and disorders in the blood. absorption of food, preferably bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. 59. The medicament according to one or more of claims 42 to 56 for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. 60. The medicament according to claim 57 for the modulation of cannabinoid receptors, preferably cannabinoid receptors 1 (CBx), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, gastrointestinal tract disorders or reproductive disorders. 61. The medicament according to one or more of claims 42 to 57 for the prophylaxis and / or treatment of disorders in the absorption of food, preferably bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity. 62. The medicament according to one or more of claims 42 to 57 for the prophylaxis and / or treatment of psychosis. 63. The medicament according to one or more of claims 42 to 57 for the prophylaxis and / or treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, drug abuse and / or addiction and / or drug abuse and / or addiction, preferably drug abuse and / or addiction and / or nicotine abuse and / or addiction. 64. The medicament according to one or more of claims 42 to 57 for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, disorders of the cerebellum, disorders spinocerebral, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathy, glaucoma, migraine, Parkinson's disease, morbid Hutington, morbid Alzheimer's disease, Raynaud's disease, tremor disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders; bone disorders that include osteoporosis or Pager's disease of bone. Cancer, preferably for the prophylaxis and / or treatment of one or more of the types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, cancer liver, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and, prostate cancer; movement disorders induced by medication, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or by potentiation of analgesic effect of narcotic analgesics and no narcotics, or to influence intestinal transit. 65. The use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of compounds according to one or more of claims 16 to 39 and optionally one or more pharmaceutically excipients. acceptable, for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and disorders in the absorption of food , especially bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. 66. The use of at least one substituted pyrazoline compound according to one or more of claims 1-15 and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of disorders of the system central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. 67. The use of at least one combination of the compounds according to one or more of claims 16 to 39 and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid receptors, preferably cannabinoid receptors. (CBX), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. 68. The use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of the compounds according to one or more of claims 16 to 39 and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicament for the prophylaxis and / or treatment of disorders in the absorption of food, preferably bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity. 69. The use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of the compounds according to one or more of claims 16 to 39 and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicament for the prophylaxis and / or treatment of psychosis. 70. The use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of the compounds according to one or more of claims 16 to 39 and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicament for the prophylaxis and / or treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, drug abuse and / or addiction and / or drug abuse and / or addiction , preferably drug abuse and / or nicotine addiction or abuse and / or addiction. 71. The use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of the compounds according to one or more of claims 16 to 39 and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellum disorders, spinocerebral disorders, cognitive disorders, cranial trauma , panic attacks, peripheral neuropathy, glaucoma, migraine, Parkinson's disease, morbid Hutington, morbid Alzheimer's disease, Raynaud's disease, tremor disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders; bone disorders that include osteoporosis or Pager's disease of bone. Cancer, preferably for the prophylaxis and / or treatment of one or more of the types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, cancer liver, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and, prostate cancer; movement disorders induced by medication, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or by potentiation of analgesic effect of narcotic analgesics and no narcotics, or to influence intestinal transit. 72. The use of at least one substituted pyrazoline compound of general formula I wherein R 1 represents hydrogen or a linear or branched C 1 -4 alkyl group, R 2, R 3 and R 4 independently of one another represents hydrogen, a linear or branched C 6 -6 alkyl group, a linear or branched C 6 -alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R8, SH, SR8, SOR, S02R8, NH2, NHR8, NR8R9, - (C = 0) -NH2, - (0 = 0) - NHR8 or - (0 = 0) -NR8R9 whereby R8 and R9 for each substituent independently represents straight or branched C6-6 alkyl, R5, R6 and R7 independently of each other represents hydrogen, an alkyl group Linear or branched C6-6, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (0 = 0) -R10 SH, SR10, SOR10, NH2 , NHR10, NR10R1: L, - (0 = 0) -NH2, - (0 = 0) - NHR10 and - (0 = 0) -NR10R1X, wherefore R10 and optionally R11 for each substituent independently represents linear or branched C? _6 alkyl; optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or an N-oxide corresponding to these, or a corresponding salt thereof, or a corresponding solvate thereof; and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the regulation of triglyceride levels in blood plasma and for the prophylaxis and / or treatment of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and disorders in the absorption of food, especially bulimia, anorexia, caquesia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), preferably obesity and diabetes. 73. The use according to claim 72, characterized in that at least one of R2, R3 or R4 represents hydrogen, while at least one of R2, R3 or R4 is different from hydrogen. 74. The use according to any one of claims 72 or 73, characterized in that at least one of Rs, R6 or R7 represents hydrogen, while at least one of R5, R6 or R7 is different from hydrogen. 75. The use according to any one of claims 72 to 74, characterized in that R2, R3 and R4 independently of one another represents hydrogen, linear or branched C? ~ 6 alkyl group, a halogen atom, or CF3, preferably R2, R3 and R4 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. 76. The use according to any one of claims 72 to 75, characterized in that R5, R6 and R7 independently of each other represents hydrogen, linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R5. , R6 and R7 independently of one another represent hydrogen, methyl, ethyl, F, Cl, Br and CF3. 77. The use according to any one of claims 72 to 76, characterized in that R2 represents a chlorine atom in the 4- position of the phenyl ring, while R3 and R4 represents hydrogen. 78. The use according to any one of claims 72 to 77, characterized in that R5 and R6 each represent chlorine atoms in the 2- and 4- position of the phenyl ring, while R7 represents hydrogen. 79. The use according to any one of claims 72 to 78, characterized in that R1 represents hydrogen, methyl or ethyl, preferably hydrogen. 80. The use according to one or more of claims 72 to 79 characterized in that the compound of general formula (I) is represented by a compound of general formula (II) wherein R1 represents hydrogen or a linear or branched C6-6 alkyl group, R12, R13, R14 or R15 independently of one another represents a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, SH, NH2, hydrogen, methyl, ethyl, F, Cl, Br and CF3, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any proportion of mixture, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate of these. 81. The use according to claim 80 characterized in that R12 and R13 independently of each other represents hydrogen, a linear or branched alkyl group, a halogen atom, or CF3, preferably R12 and R13 independently of each other represents hydrogen, methyl, ethyl , F, Cl, Br and CF3. 82. The use according to any one of claims 80 or 81, characterized in that R14, and R15 independently of one another represents hydrogen, linear or branched C6-6 alkyl group, a halogen atom, or CF3, preferably R14 and R15 independently of one another represents hydrogen, methyl, ethyl, F, Cl, Br and CF3. 83. The use according to any one of claims 80 to 82, characterized in that R13 represents Cl and R12 represents hydrogen. 8 The use according to any one of claims 80 to 83, characterized in that R14 and R15 each represent Cl. 85. Use according to any one of claims 80 to 84, characterized in that R 'represents hydrogen, methyl or ethyl, preferably hydrogen. 86. The use according to one or more of claims 72 to 85 characterized in that the compound according to the formulas I or II is selected from the group consisting of: 5- (4-chloro-phenyl) -1- (2 , 4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.